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Results
Twelve patients with genotype-negative CPVT were treated with flecainide. Conventional therapy failed to control ventricular arrhythmias in all patients. Flecainide was initiated because of significant ventricular arrhythmias (N=8), syncope (N=3), or cardiac arrest (N=1). At the baseline exercise test before flecainide, six patients had ventricular tachycardia and five patients had bigeminal or frequent ventricular premature beats. Flecainide reduced ventricular arrhythmias at the exercise test in eight patients compared to conventional therapy, similar to that in patients with genotype-positive CPVT in our previous report. Notably, flecainide completely prevented ventricular arrhythmias in seven patients. Flecainide was continued in all patients except for one who had ventricular tachycardia at the exercise test on flecainide. During a follow-up of 48±94 months, arrhythmic events (sudden cardiac death and aborted cardiac arrest) associated with noncompliance occurred in two patients. Flecainide was not discontinued owing to side effects in any of the patients.
Conclusion
Flecainide was effective in patients with genotype-negative CPVT, suggesting that spontaneous Ca 2+ release from ryanodine channels plays a role in arrhythmia susceptibility, similarly to that in patients with genotype-positive CPVT.
INTRODUCTION
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome characterized by bidirectional or polymorphic ventricular tachycardia (VT) induced by adrenergic stress in the absence of structural heart disease. [1] [2] [3] Three causative genes have been identified for CPVT: RYR2, which encodes the cardiac ryanodine receptor Ca 2+ release channel; CASQ2, which encodes cardiac calsequestrin; and TRDN, which encodes triadin; and all of them are constitutive proteins of the macromolecular Ca 2+ release complex in the sarcoplasmic reticulum. [4] [5] [6] [7] A mutation in these genes is identified in approximately 60% to 70% of patients with CPVT. 2, 8 A locus on chromosome 7p14-p22 has also been linked to CPVT, but a corresponding gene has not been identified yet. 9 Furthermore, mutations in KCNJ2 encoding the potassium inwardly-rectifying channel Kir2.1, which generally are associated with AndersenTawil syndrome, may phenocopy CPVT. 10 Treatment with β-adrenergic blockers reduces ventricular arrhythmia burden and mortality in patients with CPVT. However, the efficacy of β-blockers is not sufficiently protective and an estimated eight-year rate of fatal or near-fatal events on β-blocker therapy is 15%. 2, 3 Although the beneficial effects of the calcium channel blocker verapamil in combination with a β-blocker have been reported, [11] [12] [13] [14] the role of verapamil has not been well assessed. 2 Left cardiac sympathetic denervation has been reported to be highly effective in severely affected patients, but requires surgery and is not universally available. 15 Implantable cardioverter defibrillators (ICDs) are recommended for prevention of sudden death in patients with CPVT. 16 However, painful shocks can trigger further adrenergic stress and arrhythmias, and deaths have occurred despite appropriate ICD shocks. 17, 18 We have recently discovered that the antiarrhythmic agent flecainide inhibits Ca
2+
release from ryanodine receptor 19 and that flecainide in addition to conventional drug therapy prevents ventricular arrhythmias in CPVT patients carrying a mutation in RYR2 or CASQ2. 3 Here, we studied the efficacy and safety of flecainide in CPVT patients with no mutations in RYR2, CASQ2 and KCNJ2, who have similar risk of arrhythmia events to genotype-positive patients.
2

METHODS
Study population
This study included all consecutive patients with genotype-negative CPVT in whom flecainide was started because of the insufficient efficacy of conventional therapy with β-blockers with or without verapamil at five tertiary referral centers in the Netherlands, the United Kingdom, Israel, Japan, and Germany. All patients had a clinical diagnosis of CPVT based on adrenergic stress-induced bidirectional or polymorphic VT in the absence of structural heart abnormalities by echocardiography. 20 All families received genetic counseling and all investigated individuals consented to both cardiologic evaluation and genetic testing. Patients were screened for a putative pathogenic mutation in all exons of RYR2, CASQ2, and KCNJ2. Only individuals who were not carrying proven or putative pathogenic mutations in all of these genes were included. Decisions on administration of flecainide and its dose were made by the local cardiologists. Data collection and analysis were done retrospectively by chart review. Patients in whom the dose of β-blocker or verapamil was increased after the initiation of flecainide were not included in this study.
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Outcome measures
The efficacy of flecainide on CPVT was compared between the last exercise test on conventional therapy and the first exercise test on a stable dose of flecainide after ≥5 days of the initiation. Exercise testing was performed using treadmill (standard or modified Bruce protocols) or bicycle ergometer, depending on institutions. Ventricular arrhythmias during exercise testing were quantified using the ventricular arrhythmia score defined by the worst ventricular arrhythmia observed: 1, no or isolated ventricular premature beats VPBs; 2, bigeminal VPBs and/ or >10 VPBs per minute; 3, couplet; 4, non-sustained VT. 20 In addition, the presence of either of the parameters of the ventricular arrhythmia score, sinus rate at the onset of ventricular ectopy (most often an isolated VPB), the maximum number of VPBs during a 10-second period and the ratio of VPBs to sinus beats during the 10-second period with the maximum number of VPBs were analyzed. The effects of flecainide on arrhythmic events including syncope, aborted cardiac arrest, appropriate ICD shocks, and sudden cardiac death during follow-up were also assessed.
Data analysis
Values are expressed as mean ± standard deviation. To study the effects of flecainide during exercise testing, related data were compared using the paired Wilcoxon signed-rank test for continuous and ordinal variables and the McNemar test for dichotomous variables. All statistical analyses were performed with SPSS, version 20.0 (SPSS Inc., Chicago, IL). A two-sided P <0.05 was considered statistically significant.
RESULTS
Patient characteristics
We identified 12 patients with genotype-negative CPVT who received flecainide (Table 1) . Mean age at baseline was 22±11 years, and six patients were female. Our cohort included seven patients with a family history of CPVT (six probands and one family member). Nine patients had a history of syncope and/or cardiac arrest. In patient 6, a common variant of unknown significance (VUS), p.Val507Ile, was identified in RYR2. Patient 11 tested heterozygote positive for two new VUS in CASQ2: c.158G>T (p.Cys53Phe) and c.838+3A>G. The c.158G>T VUS was once detected in 13 000 control alleles, whereas the c.838+3A>G may affect splicing at the donorsite of exon 8 and was not detected in 13 000 control alleles. Before the initiation of flecainide, β-blockers failed to suppress ventricular arrhythmias in all patients. In seven patients, multiple drugs including β-blockers, verapamil, and other antiarrhythmic drugs failed to suppress ventricular arrhythmias before flecainide was initiated.
Effects of flecainide on exercise-induced ventricular arrhythmias
Among genotype-negative patients, six patients (50%) had VT and five patients (42%) had couplet or bigeminal VPBs at the baseline exercise testing before flecainide administration (Tables 1 and 2 ). In a remaining patient who had syncope during a combination therapy with propranolol and verapamil (patient 3), there was no ventricular arrhythmia during the baseline exercise testing. Flecainide improved the ventricular arrhythmia score at exercise testing in eight patients (67%) compared to that during conventional therapy (Figure 1 ), while the maximum workload during flecainide therapy was increased compared to that during conventional drug therapy ( Table 2 ). The effects of flecainide seemed similar to that in genotype-positive patients in our previously report (76%). 20 Flecainide completely suppressed ventricular arrhythmias in seven patients (58%) and suppressed VT in four of the six patients who developed VT during the baseline testing. Compared to the baseline exercise test, flecainide reduced the maximum number of VPBs during a 10-seconds period. In one patient (patient 10), flecainide was discontinued because of VT during exercise testing.
Effects of flecainide on arrhythmia events
A total of 11 patients (92%) continued to receive flecainide and were included in the further analysis of the incidence of arrhythmic events. During a mean follow-up of 48±94 months, arrhythmic events associated with noncompliance occurred in two of 11 patients with genotypenegative CPVT. Patients 6 died suddenly while playing soccer. Although flecainide combined with nadolol suppressed VTs during exercise testing, the patient self-discontinued the drug therapy after his last visit to the clinic. Patient 1 collapsed and was resuscitated by his relatives. The patient had not taken flecainide from the night before the collapse, and the serum level of flecainide was low (0.13 mg/L; therapeutic range, 0.4-0.9 mg/L) at the event. Metoprolol and flecainide were resumed at the previous doses, and no event occurred thereafter. In the remaining nine patients, there was no arrhythmic event during the follow-up period, while seven of the nine patients had arrhythmic events despite conventional drug therapy before the initiation of flecainide. Flecainide was not discontinued due to side effect in any of the patients. 
DISCUSSION
In this study, flecainide suppressed ventricular arrhythmias during exercise testing in patients with genotype-negative CPVT, similar to that in patients with genotype-positive CPVT. Flecainide was highly effective in preventing arrhythmic events during a long-term follow-up. CPVT has been associated with mutations in RYR2, CASQ2, and TRDN. [4] [5] [6] [7] Mutations in these genes destabilize the ryanodine channel complex in the sarcoplasmic reticulum and result in spontaneous Ca 2+ release through the ryanodine channel leading to delayed after depolarizations, triggered activity, and VT. [21] [22] [23] [24] Recently, we and others have identified the therapeutic effects of flecainide in CPVT. 19, 25, 26 Flecainide directly inhibits the ryanodine channel and suppresses delayed afterdepolarizations and triggered activity in mutant cardiomyocytes in which RYR2 or CASQ2 loci are modified. 19, 26, 27 In our mouse model of CPVT, flecainide prevents spontaneous VT and inducible VT by exercise or isoproterenol. 19 Yet, we have recently discovered that flecainide prevents CPVT in patients carrying a mutation in RYR2 or CASQ2, possibly resulting in spontaneous Ca2+ release. 19, 20 In this study, flecainide was also effective in patients with genotype-negative CPVT, similar to that in patients with genotype-positive CPVT in our prior study. 20 Notably, all arrhythmic events during flecainide therapy were associated with noncompliance in our present and prior studies. 20 The efficacy of flecainide in genotype-negative CPVT patients suggests that uncontrolled Ca2+ release through the ryanodine channel is also important as the underlying mechanisms in patients without an identified mutation in RYR2 or CASQ2, that account for 30% to 40% of patients with CPVT. 3, 28 There are a certain number of CPVT patients with positive family 7 Furthermore, flecainide may suppress CPVT through sodium channel blocking effects as we and others have previously proposed. 19, 26 Genotype-phenotype correlations have been studied in inherited arrhythmia syndromes. The genotype contributes to risk stratification and impacts on therapeutic decisions in long-QT syndrome; the most studied arrhythmia syndrome. 29 In CPVT, the risk of arrhythmia events and the efficacy of β-blocker seem to be similar in patients with genotype-positive and genotypenegative CPVT. 2 Our findings indicate that flecainide can be used regardless of genotyping results in CPVT patients in whom β-blockers fail to control their ventricular arrhythmias or symptoms. Our study has several limitations. The number of patients was limited because CPVT is a very rare disease. Therefore, the efficacy of flecainide could not be systematically assessed and further studies, probably randomized controlled studies, are needed. 30 Patients with CPVT whose arrhythmias are refractory to the conventional drug therapy were included in this study and our previous study. 20 Therefore, the efficacy of flecainide in patients whose arrhythmias are well responded to the conventional therapy is not known. Exercise testing is used to assess the effects of therapies in CPVT and our previous study showed that ventricular arrhythmia scores at exercise testing are reproducible measures of drug efficacy in CPVT. 20 However, the predictive ability of ventricular arrhythmia scores for arrhythmia events is not clear. Finally, the patients in this study were not tested for mutations in TRDN. 7 However, in this study, none of the patients were from a consanguineous family, so the possibility of identifying mutations in TRDN seems low.
CONCLUSION
In conclusion, we found that flecainide was effective in suppressing ventricular arrhythmias during exercise and preventing arrhythmia events in patients with genotype-negative CPVT, similar to that in patients with genotype-positive CPVT. Our results suggest that flecainide can be added, regardless of genotype, to control ventricular arrhythmias or symptoms when they are insufficiently controlled by conventional therapy with β-blockers.
